AbbVie to present IBD data at UEGW 2026
The release headline says data on long-term clinical and endoscopic outcomes for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) across inflammatory bowel disease will be highlighted at UEGW 2026.
The release headline says data on long-term clinical and endoscopic outcomes for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) across inflammatory bowel disease will be highlighted at UEGW 2026.